Open Access

Efficacy and side effects of pembrolizumab plus chemotherapy vs. chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A meta‑analysis

  • Authors:
    • Jinquan Li
    • Xiaosheng Hu
    • Shanzhong Zhang
  • View Affiliations

  • Published online on: June 12, 2024     https://doi.org/10.3892/ol.2024.14504
  • Article Number: 371
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Recently, the treatment plan of pembrolizumab plus chemotherapy was regarded as a promising treatment for patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJC). However, the efficacy and side effects of pembrolizumab plus chemotherapy still lack evidence‑based medical evidence to support. Therefore, a meta‑analysis was conducted to evaluate the hot issue. By searching PubMed, EMBASE, Cochrane Library, Web of Science, any randomized clinical studies of pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced GC/GEJC met the inclusion criteria were included. The quality of the literature was evaluated and the data was extracted. A correlative software was also used to analyze the data and to draw a conclusion. After screening 14,015 studies, four studies were eligible for the meta‑analysis. Compared with chemotherapy alone group, the overall survival (OS) rate was significantly longer. In programmed cell death ligand 1 (PD‑L1) combined positive score (CPS) ≥1 subgroup and PD‑L1 CPS ≥10 subgroup analyses, the results showed that the response rate (RR) and complete response rate (CR) were both higher in pembrolizumab plus chemotherapy group compared with chemotherapy alone group. There were not significant differences in the CR, the treatment‑related adverse events, succumbed to drug‑related events and succumbed to immune‑mediated events between the two groups. However, the effect events such as the treatment‑related adverse events led to discontinuation, the 3‑5 treatment‑related adverse events and the immune‑mediated adverse events and infusion reactions were more common in pembrolizumab plus chemotherapy group. In conclusion, the current meta‑analysis revealed that, in treating advanced GC/GEJC, pembrolizumab plus chemotherapy had improved therapeutic efficacies than chemotherapy alone, as evidenced by the significantly longer OS. Furthermore, the patients in PD‑L1 CPS ≥1 subgroup and PD‑L1 CPS ≥10 subgroup appeared to benefit from pembrolizumab plus chemotherapy treatment because of higher RR and CR. However, side effects such as the treatment‑related adverse events leading to discontinuation, the 3‑5 treatment‑related adverse events, and immune‑mediated adverse events and infusion reactions deserved more attention.
View Figures
View References

Related Articles

Journal Cover

August-2024
Volume 28 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li J, Hu X and Zhang S: Efficacy and side effects of pembrolizumab plus chemotherapy vs. chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A meta‑analysis. Oncol Lett 28: 371, 2024.
APA
Li, J., Hu, X., & Zhang, S. (2024). Efficacy and side effects of pembrolizumab plus chemotherapy vs. chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A meta‑analysis. Oncology Letters, 28, 371. https://doi.org/10.3892/ol.2024.14504
MLA
Li, J., Hu, X., Zhang, S."Efficacy and side effects of pembrolizumab plus chemotherapy vs. chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A meta‑analysis". Oncology Letters 28.2 (2024): 371.
Chicago
Li, J., Hu, X., Zhang, S."Efficacy and side effects of pembrolizumab plus chemotherapy vs. chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A meta‑analysis". Oncology Letters 28, no. 2 (2024): 371. https://doi.org/10.3892/ol.2024.14504